Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 1.00 |
| ▸ | IDO1 | P14902 | 6/20 | 0.59 |
| ▸ | METAP2 | P50579 | 9/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PAK4 | O96013 | 1/20 | 0.49 |
| ▸ | PIM1 | P11309 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | METAP1 | P53582 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21792290 | 0.85 | NOTUM (1.00) | NOTUMIDO1METAP2XDHSLC22A12 | |
| SCHEMBL30567505 | 0.70 | IDO1 (0.56) | NOTUMIDO1METAP2METAP1 | |
| SCHEMBL13070907 | 0.70 | NOTUM (0.54) | NOTUMJAK2KDRAURKB | |
| SCHEMBL104083 | 0.70 | METAP2 (0.64) | NOTUMIDO1METAP2JAK2ROCK2 | |
| SCHEMBL21776857 | 0.69 | NOTUM (0.53) | NOTUM | |
| SCHEMBL29626826 | 0.66 | METAP2 (1.00) | NOTUMIDO1METAP2METAP1 | |
| SCHEMBL8221447 | 0.65 | METAP2 (1.00) | NOTUMIDO1METAP2METAP1 | |
| SCHEMBL3994808 | 0.64 | NOTUM (0.47) | NOTUM | |
| SCHEMBL2751446 | 0.64 | NOTUM (0.47) | NOTUM | |
| SCHEMBL2753317 | 0.64 | NOTUM (0.47) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | NOTUM 5/4885IDO1 4116/4885METAP2 2776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.